Gencurix Inc (KQ:229000) — Market Cap & Net Worth
Market Cap & Net Worth: Gencurix Inc (229000)
Gencurix Inc (KQ:229000) has a market capitalization of $25.56 Million (₩37.72 Billion) as of May 2, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #24247 globally and #1766 in its home market, demonstrating a 2.18% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gencurix Inc's stock price ₩2340.00 by its total outstanding shares 16117826 (16.12 Million). Analyse how efficiently does Gencurix Inc generate cash to see how efficiently the company converts income to cash.
Gencurix Inc Market Cap History: 2020 to 2026
Gencurix Inc's market capitalization history from 2020 to 2026. Data shows change from $160.36 Million to $25.56 Million (-30.26% CAGR).
Index Memberships
Gencurix Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$299.07 Billion | 0.01% | #941 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$299.07 Billion | 0.01% | #941 of 1384 |
Weight: Gencurix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Gencurix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gencurix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Gencurix Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $160.36 Million | $1.57 Billion | $33.11 Billion | 0.10x | 0.00x |
| 2021 | $173.97 Million | $3.05 Billion | -$34.67 Billion | 0.06x | N/A |
| 2022 | $67.25 Million | $2.56 Billion | -$24.60 Billion | 0.03x | N/A |
| 2023 | $67.94 Million | $2.60 Billion | -$19.26 Billion | 0.03x | N/A |
| 2024 | $21.52 Million | $5.13 Billion | -$3.63 Billion | 0.00x | N/A |
Competitor Companies of 229000 by Market Capitalization
Companies near Gencurix Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Gencurix Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Gencurix Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Gencurix Inc's market cap moved from $160.36 Million to $ 25.56 Million, with a yearly change of -30.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩25.56 Million | +50.87% |
| 2025 | ₩16.94 Million | -21.27% |
| 2024 | ₩21.52 Million | -68.33% |
| 2023 | ₩67.94 Million | +1.02% |
| 2022 | ₩67.25 Million | -61.34% |
| 2021 | ₩173.97 Million | +8.48% |
| 2020 | ₩160.36 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Gencurix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $25.56 Million USD |
| MoneyControl | $25.56 Million USD |
| MarketWatch | $25.56 Million USD |
| marketcap.company | $25.56 Million USD |
| Reuters | $25.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gencurix Inc
Gencurix Inc. provides diagnostic solutions in South Korea. Its products include GenesWell BCT, a multigene diagnostic test for breast cancer; Droplex, a genetic test based on digital PCR platform; eDX, an early diagnosis for cancer with liquid biopsy; GenePro SARS-CoV-2 Test kit; GenoCTC, a circulating tumor cell isolator; and GenePro LAMP Cycler, a portable device for infectious disease detecti… Read more